Carin Jorup
About
Carin Jorup is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Animal Science and Zoology.
According to data from OpenAlex, Carin Jorup has authored 32 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Physiology, 29 papers in Pulmonary and Respiratory Medicine and 2 papers in Animal Science and Zoology. Recurrent topics in Carin Jorup's work include Asthma and respiratory diseases (29 papers), Inhalation and Respiratory Drug Delivery (22 papers) and Respiratory and Cough-Related Research (16 papers). Carin Jorup is often cited by papers focused on Asthma and respiratory diseases (29 papers), Inhalation and Respiratory Drug Delivery (22 papers) and Respiratory and Cough-Related Research (16 papers). Carin Jorup collaborates with scholars based in Sweden, United Kingdom and Canada. Carin Jorup's co-authors include Paul M. O’Byrne, Helen K. Reddel, Tito Atienza, Klaus F. Rabe, J. Mark FitzGerald, Peter J. Barnes, Eric D. Bateman, Christina Keen, Rosa Lamarca and Nanshan Zhong and has published in prestigious journals such as New England Journal of Medicine, The Lancet and American Journal of Respiratory and Critical Care Medicine.
In The Last Decade
Carin Jorup
32 papers receiving 2.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Carin Jorup Sweden | 16 | 1.9k | 1.8k | 202 | 103 | 69 | 32 | 2.1k | ||
| Steven Pascoe United Kingdom | 17 | 2.1k 1.1× | 2.5k 1.4× | 42 0.2× | 58 0.6× | 51 0.7× | 49 | 2.7k | ||
| Edward Dompeling Netherlands | 14 | 733 0.4× | 757 0.4× | 75 0.4× | 49 0.5× | 15 0.2× | 24 | 1.1k | ||
| Manuel Soto‐Quiroz Costa Rica | 6 | 719 0.4× | 536 0.3× | 155 0.8× | 47 0.5× | 19 0.3× | 7 | 951 | ||
| Cynthia Caracta United States | 21 | 1.2k 0.6× | 1.4k 0.8× | 109 0.5× | 12 0.1× | 26 0.4× | 92 | 1.7k | ||
| Christopher Burgess United Kingdom | 9 | 503 0.3× | 391 0.2× | 46 0.2× | 63 0.6× | 11 0.2× | 30 | 939 | ||
| Carlos Cézar Fritscher Brazil | 17 | 605 0.3× | 579 0.3× | 41 0.2× | 38 0.4× | 23 0.3× | 40 | 973 | ||
| Makiko Jinnai Japan | 21 | 934 0.5× | 928 0.5× | 113 0.6× | 16 0.2× | 5 0.1× | 28 | 1.3k | ||
| Daniel Menzies United Kingdom | 15 | 628 0.3× | 498 0.3× | 84 0.4× | 7 0.1× | 13 0.2× | 30 | 994 | ||
| Lars Christian Laursen Denmark | 13 | 387 0.2× | 521 0.3× | 131 0.6× | 8 0.1× | 15 0.2× | 23 | 709 | ||
| José María Guerrero Vega Spain | 18 | 325 0.2× | 311 0.2× | 444 2.2× | 52 0.5× | 7 0.1× | 48 | 1.3k |
Countries citing papers authored by Carin Jorup
Since
Specialization
Citations
This map shows the geographic impact of Carin Jorup's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carin Jorup with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carin Jorup more than expected).
Fields of papers citing papers by Carin Jorup
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Carin Jorup. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carin Jorup. The network helps show where Carin Jorup may publish in the future.
Co-authorship network of co-authors of Carin Jorup
This figure shows the co-authorship network connecting the top 25 collaborators of Carin Jorup. A scholar is included among the top collaborators of Carin Jorup based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carin Jorup. Carin Jorup is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Reddel, Helen K., Guy Brusselle, Rosa Lamarca, et al.. (2023). Safety and Effectiveness of As-Needed Formoterol in Asthma Patients Taking Inhaled Corticosteroid (ICS)-Formoterol or ICS-Salmeterol Maintenance Therapy. The Journal of Allergy and Clinical Immunology In Practice. 11(7). 2104–2114.e3.
2.
Bateman, Eric D., Helen K. Reddel, Paul M. O’Byrne, et al.. (2018). As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma. New England Journal of Medicine. 378(20). 1877–1887.
3.
Ferguson, Gary T., Donald P. Tashkin, Tor Skärby, et al.. (2017). Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. Respiratory Medicine. 132. 31–41.
4.
O’Byrne, Paul M., J. Mark FitzGerald, Nanshan Zhong, et al.. (2017). The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given ‘as needed’ in mild asthma: study protocols for two randomised controlled trials. Trials. 18(1). 12–12.
5.
Hollis, Sally, et al.. (2017). Risk of pneumonia with budesonide-containing treatments in COPD: an individual patient-level pooled analysis of interventional studies. International Journal of COPD. Volume 12. 1071–1084.
6.
Pearlman, David S., Julie McLaren, Rosa Lamarca, et al.. (2017). Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6–<12 years). Annals of Allergy Asthma & Immunology. 118(4). 489–499.e1.
7.
Nordenmark, Lars H., et al.. (2015). Feasibility of Computed Tomography in a Multicenter COPD Trial: A Study of the Effect of AZD9668 on Structural Airway Changes. Advances in Therapy. 32(6). 548–566.
8.
Bjermer, Leif, Piotr Kuna, Carin Jorup, Thomas Bengtsson, & Johan Rosenborg. (2015). Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β2-adrenoreceptor agonist (uLABA). Drug Design Development and Therapy. 9. 753–753.
9.
Gauvreau, Gail M., Louis‐Philippe Boulet, Richard Leigh, et al.. (2014). A Nonsteroidal Glucocorticoid Receptor Agonist Inhibits Allergen-induced Late Asthmatic Responses. American Journal of Respiratory and Critical Care Medicine. 191(2). 161–167.
10.
Kuna, Piotr, Yavor Ivanov, Takefumi Saito, et al.. (2013). Efficacy and safety of AZD3199 vs formoterol in COPD: a randomized, double-blind study. Respiratory Research. 14(1). 64–64.
11.
Bjermer, Leif, Thomas Bengtsson, Carin Jorup, & Jan Lötvall. (2012). Local and systemic effects of inhaled AZD9164 compared with tiotropium in patients with COPD. Respiratory Medicine. 107(1). 84–90.
12.
Bjermer, Leif, Thomas Bengtsson, & Carin Jorup. (2012). A Comparison of the Local and Systemic Effects of AZD3199, an Inhaled Ultra-long-acting β2-adrenoceptor Agonist (uLABA), With Formoterol in Patients With Asthma. Journal of Allergy and Clinical Immunology. 129(2). AB241–AB241.
13.
Kuna, Piotr, Matthew Peters, A I Manjra, et al.. (2007). Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice. 61(5). 725–736.
14.
Rabe, Klaus F., Emílio Pizzichini, Björn Ställberg, et al.. (2006). Budesonide/Formoterol in a Single Inhaler for Maintenance and Relief in Mild-to-Moderate Asthma. CHEST Journal. 129(2). 246–256.
15.
Pohunek, Petr, Piotr Kuna, Carin Jorup, & K. De Boeck. (2006). Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma1. Pediatric Allergy and Immunology. 17(6). 458–465.
16.
Rabe, Klaus F., Tito Atienza, Pál Magyar, et al.. (2006). Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. The Lancet. 368(9537). 744–753.
17.
Balanag, Vincent M., Faisal Yunus, Pan‐Chyr Yang, & Carin Jorup. (2005). Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulmonary Pharmacology & Therapeutics. 19(2). 139–147.
18.
Aalbers, René, Vibeke Backer, T Kava, et al.. (2004). Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Current Medical Research and Opinion. 20(2). 225–240.
19.
Schumacher, G, B. Kollberg, Bengt Sandstedt, et al.. (1993). A Prospective Study of First Attacks of Inflammatory Bowel Disease and Non-Relapsing Colitis: Microbiologic Findings. Scandinavian Journal of Gastroenterology. 28(12). 1077–1085.
20.
Hellstrand, Per, Carin Jorup, & Marie‐Louise Lydrup. (1984). O2 consumption, aerobic glycolysis and tissue phosphagen content during activation of the NA+/K+ pump in rat portal vein. Pflügers Archiv - European Journal of Physiology. 401(2). 119–124.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Steven Pascoe Breakdown of academic impact, for papers by Edward Dompeling Breakdown of academic impact, for papers by Manuel Soto‐Quiroz Breakdown of academic impact, for papers by Cynthia Caracta Breakdown of academic impact, for papers by Christopher Burgess Breakdown of academic impact, for papers by Carlos Cézar Fritscher Breakdown of academic impact, for papers by Makiko Jinnai Breakdown of academic impact, for papers by Daniel Menzies Breakdown of academic impact, for papers by Lars Christian Laursen Breakdown of academic impact, for papers by José María Guerrero Vega